Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNASDAQ:CLRBNASDAQ:PMNNASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.22-6.5%$0.24$0.15▼$13.00$13.07M-0.035.82 million shs2.03 million shsCLRBCellectar Biosciences$0.41-5.4%$0.29$0.22▼$3.34$19.04M0.523.99 million shs2.64 million shsPMNProMIS Neurosciences$0.52-0.1%$0.55$0.47▼$2.37$16.98M-0.0878,750 shs19,524 shsTHARTharimmune$1.29-5.8%$1.37$0.95▼$6.39$3.43M1.04374,440 shs40,496 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-7.05%+2.23%+30.30%-55.11%+21,499,900.00%CLRBCellectar Biosciences-5.45%+14.52%+71.67%+30.93%-87.59%PMNProMIS Neurosciences-0.10%+8.68%+2.87%-32.18%-69.08%THARTharimmune-5.84%-14.56%-7.86%-11.03%-58.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/ACLRBCellectar Biosciences2.6731 of 5 stars3.25.00.00.03.30.00.6PMNProMIS Neurosciences2.3282 of 5 stars3.52.00.00.03.30.80.6THARTharimmune3.0992 of 5 stars3.85.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,760.47% UpsideCLRBCellectar Biosciences 2.33Hold$12.502,925.17% UpsidePMNProMIS Neurosciences 3.00Buy$4.50766.22% UpsideTHARTharimmune 3.50Strong Buy$17.001,217.83% UpsideCurrent Analyst Ratings BreakdownLatest THAR, CLRB, PMN, and ABP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/12/2025PMNProMIS NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K71.42N/AN/AN/A∞CLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/APMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ATHARTharimmuneN/AN/AN/AN/A$195.44 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbproN/AN/A0.00∞N/AN/AN/AN/AN/ACLRBCellectar Biosciences-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/11/2025 (Estimated)PMNProMIS Neurosciences-$13.21M-$0.05N/AN/AN/AN/A-636.20%-130.32%8/6/2025 (Estimated)THARTharimmune-$9.32M-$7.88N/A∞N/AN/A-167.63%-130.18%N/ALatest THAR, CLRB, PMN, and ABP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17-$0.13+$0.04-$0.14N/AN/A5/12/2025Q1 2025PMNProMIS Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A5/12/2025Q1 2025THARTharimmune-$0.84-$0.99-$0.15-$0.99N/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/25/2025Q4 2024THARTharimmuneN/A-$2.02N/A-$2.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/AN/AN/ACLRBCellectar BiosciencesN/A1.771.77PMNProMIS NeurosciencesN/A9.309.30THARTharimmuneN/A2.352.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%CLRBCellectar Biosciences16.41%PMNProMIS Neurosciences50.13%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%CLRBCellectar Biosciences5.04%PMNProMIS Neurosciences6.11%THARTharimmune10.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million4.57 millionN/ACLRBCellectar Biosciences1046.08 million44.38 millionOptionablePMNProMIS Neurosciences532.69 million31.25 millionNot OptionableTHARTharimmune22.66 million1.89 millionNot OptionableTHAR, CLRB, PMN, and ABP HeadlinesRecent News About These CompaniesTharimmune announces executive changes and new agreementsJune 13 at 3:42 PM | investing.comTharimmune advances opioid prophylaxis drug TH104May 7, 2025 | investing.comTharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA FeedbackMay 6, 2025 | accessnewswire.comTharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL ConferencesMay 1, 2025 | accessnewswire.comTharimmune Appoints Clay Kahler and Gary Stetz to its Board of DirectorsApril 30, 2025 | accessnewswire.comTharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA FeedbackApril 28, 2025 | sacbee.comTharimmune announces board retirements ahead of annual meetingApril 26, 2025 | investing.comTharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | finanznachrichten.deTharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | accessnewswire.comTharimmune reports data on new biparatopic biologicsApril 9, 2025 | bioworld.comTharimmune announces preclinical data from expanded pipeline with HS1940April 9, 2025 | markets.businessinsider.comTharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) TechnologyApril 7, 2025 | accessnewswire.comTharimmune receives Nasdaq non-compliance noticeApril 6, 2025 | investing.comTharimmune announces FDA feedback on NDA path for TH104April 1, 2025 | markets.businessinsider.comTharimmune announces FDA feedback on TH104 NDA pathApril 1, 2025 | markets.businessinsider.comTharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid ExposureMarch 31, 2025 | accessnewswire.comTharimmune announce preclinical TH023 resultsMarch 25, 2025 | markets.businessinsider.comTharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alphaMarch 24, 2025 | accessnewswire.comTharimmune leverages Epiclick platform to expand pipelineMarch 6, 2025 | bioworld.comTharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick TechnologyMarch 4, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTHAR, CLRB, PMN, and ABP Company DescriptionsAbpro NASDAQ:ABP$0.22 -0.02 (-6.52%) As of 06/13/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Cellectar Biosciences NASDAQ:CLRB$0.41 -0.02 (-5.45%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.35 -0.06 (-14.33%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.ProMIS Neurosciences NASDAQ:PMN$0.52 0.00 (-0.19%) As of 06/13/2025 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Tharimmune NASDAQ:THAR$1.29 -0.08 (-5.84%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.31 +0.02 (+1.55%) As of 06/13/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
